



## Consulta de Atención Farmacéutica Patologías Viricas

### Top Ten Artículos Mes Octubre

- Panel de expertos de GeSIDA y Plan Nacional sobre el Sida. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento anti-retroviral en adultos con infección por el virus de la inmunodeficiencia humana (Actualización enero 2015) Enferm Infect Microbiol Clin. 2015; 33(8):543.e1–543.e43.
- Documento de Consenso sobre profilaxis postexposición ocupacional y no ocupacional en relación con el VIH, VHB y VHC en adultos y niños. Enferm Infect Microbiol Clin. 2015;In press
- Mussini C. et al. European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements. HIV Medicine (2015)
- Erlandson KM et al. Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. CID 2015:61
- Ferrer E et al. Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status. J Antimicrob Chemother doi:10.1093/jac/dkv272
- Colbers A et al. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clinical Infectious Diseases 2015;61(10):1582–9
- O'Brien TR et al. No Scientific Basis to Restrict 8 Weeks of Treatment with Ledipasvir/Sofosbuvir to Patients with HCV RNA <6,000,000 IU/ml. [Hepatology](#). 2015 Oct. In press
- Kattakuzhy S et al. Six-week Combination Directly Acting Anti-HCV Therapy Induces Moderate Rates of Sustained Virologic Response in Patients with Advanced Liver Disease. CID 2015 in press.
- Sundaram V. and Kowdley K. Management of chronic hepatitis B infection. BMJ 2015;351:h4263 doi: 10.1136/bmj.h4263
- Jongbloed K et al. Recent Evidence for Emerging Digital Technologies to Support Global HIV Engagement in Care. Curr HIV/AIDS Rep DOI 10.1007/s11904-015-0291-7